We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Investors

Bioxodes is a Belgian private clinical stage company, founded in 2013. The Company has received fundings from both public and private investors and is now looking for Series B funding.

Why Invest

video testimonial

Watch our CEO Marc Dechamps present Bioxodes to investors in Zurich

with support from world-renowned stroke expert Prof Robin Lemmens, head of the stroke unit at the University Hospital Leuven (Belgium), and Hans Warrinnier, Bioxodes' Chief Medical Officer.

Investors

Public & private investors

Private Equity
(Euros)

22 million
22 million

Grants/subsidies from the Walloon Region
(Euros)

12 million
12 million

Investors

Who invests?

Investors

Why invest?

Invest in us

  • First-in-class lead compound with solid preclinical and Phase 1 clinical data, now supported by compelling interim data from the ongoing Phase 2a trial in intracerebral hemorrhage (ICH).

  • Discovery program for innovative pipeline to extend value capture beyond thrombo-inflammation.

  • Leadership and expertise with international advisor network.

  • Patent portfolio wholly owned with coverage beyond 2040.

Investors

Invest in us

Get in touch and explore our investment opportunities

investment@bioxodes.com